Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019
Octapharma has announced that the final results of the NuProtect study will be presented by Dr Ri Liesner (Great Ormond Street Hospital for Children, London, UK) as an oral presentation at the 61st Annual Meeting of the American Society of Hematology (ASH) 2019 in Orlando, Florida.
Dr Liesner commented that “I am excited to be representing the NuProtect study group to share these data. The data should help to inform clinical decision-making and provide valuable evidence to reassure clinicians and patients that Nuwiq® is an effective treatment option for PUPs”.
The NuProtect study is the largest prospective study of a single FVIII concentrate in true PUPs with haemophilia A. The study assessed the immunogenicity, efficacy and safety of the human cell line-derived recombinant FVIII Nuwiq® (simoctocog alfa) in 108 PUPs. Final results on the immunogenicity, efficacy and safety of Nuwiq® will be shared for the first time at an oral presentation on Monday 9th December.
“We are proud to present these important data in PUPs, which showcase the clinical features of Nuwiq® founded on its human cell line origin” said Larisa Belyanskaya, Head of IBU Haematology at Octapharma. Olaf Walter, Board Member at Octapharma, added that “The NuProtect study data add to the growing portfolio of clinical experience with Nuwiq® and support our goal at Octapharma to improve the lives of people with bleeding disorders”.
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1. Treatment of previously untreated patients (PUPs) with Nuwiq® was assessed in the NuProtect study. In an interim analysis of 66 patients, the cumulative incidence of high-titre inhibitors was 12.8%, and the cumulative incidence of all inhibitors was 20.8%2. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations3. Nuwiq® is approved in 59 countries for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups3.
About the NuProtect study
The NuProtect study (NCT01712438) was a prospective, multicentre, multinational, open-label, non-controlled phase III study to assess the immunogenicity, efficacy and safety of Nuwiq® in patients with severe haemophilia A and without any previous exposure to FVIII concentrates or blood products containing FVIII. Patients were treated with Nuwiq® for 100 exposure days or up to 5 years. The study was conducted at 38 sites in 17 countries. A total of 110 patients were enrolled. Of these, 108 patients were treated with Nuwiq®.
About Haemophilia A
Haemophilia A is an X-linked hereditary bleeding disorder caused by a deficiency of factor VIII (FVIII) which, if left untreated, may lead to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. The disorder affects around one in every 10,000 males worldwide. Prophylaxis with replacement FVIII therapy reduces the number of bleeding episodes and the risk of permanent joint damage.
The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.
In 2018, the Group achieved €1.8 billion in revenue, an operating income of €346 million and invested €240 million into R&D and in capital expenditures in order to ensure future prosperity. Octapharma employs 8,314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care (bleeding management and functional volume replacement)
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.
1. Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
2. Liesner R et al. Haemophilia 2018; 24:211-20.
3. Nuwiq® Summary of Product Characteristics.
Octapharma AG Contacts:
Octapharma AG International Business Unit - Haematology
Tel: +41 55 4512121
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Disruptive.Asia Comments on How Huawei and ONDE Are Helping Thailand Fight COVID-19 and Go Digital at the Same Time3.8.2020 11:00:00 EEST | Press release
Disruptive.Asia has talked to Vunnaporn Devahastin, Secretary General of the Office of the National Digital Economy and Society Commission (ONDE) of Thailand, which is collaborating with Huawei Technologies on various fronts to not only fight COVID-19 with digital technologies, but advance and accelerate Thailand’s efforts to become a digital nation, in this week’s Huawei Better World Summit. According to Vunnaporn Devahastin, there are 3 key ONDE initiatives to combat COVID-19, which are enabling government agencies and state enterprises to implement work-from-home (WFH) policies, raising sellers’ capabilities in e-commerce and enhancing rural connectivity, and providing financial support to create the Digital Economy and Society (DES) Development Fund. Meanwhile, Thailand’s Ministry of Digital Economy and Society (MDES) has been working with Huawei Technology (Thailand) Co Ltd to find ways that medical staff can leverage advanced digital technologies powered by the integration of 5G,
REPLY: Protocube Reply Presents Its Virtual Interactive Showroom Solution for the Virtualization of Environments and Products3.8.2020 10:30:00 EEST | Press release
Protocube Reply, the Reply Group company specializing in the creation of virtual environments, makes available from today its Virtual Interactive Showroom solution aimed at virtualizing environments and products for B2C and B2B markets. Through the potential offered by 3D technology, the solution enables an effective digital transposition of objects and events traditionally necessitated by physical interaction - such as exhibition venues, trade shows and consumer products - and aims to respond to the needs for new opportunities and forms of business outlined by the companies and customers that were most affected by the COVID-19 outbreak. Virtual Interactive Showroom is aimed in particular at operators and players in the trade fair industry thanks to its high level of involvement and engagement with customers and visitors (buyers, retailers, end customers). The solution allows for the seamless exploration of virtual environments, either independently or with the support of remote operat
Simpson Thacher Adds Leading Private Equity Lawyer James Howe3.8.2020 10:00:00 EEST | Press release
Simpson Thacher & Bartlett LLP announced today that James Howe has joined its Mergers and Acquisitions Practice as a Partner in the London office. “We are very pleased to welcome James to Simpson Thacher,” said Bill Dougherty, Chairman of Simpson Thacher’s Executive Committee. “His extensive experience advising private equity firms and financial institutions on complex deals in the United Kingdom, continental Europe and around the world will further enhance our strong London-based platform.” James is a rising star in private equity M&A who focuses on cross-border leveraged buyouts, mergers and acquisitions and corporate finance transactions. He has advised a wide range of clients across the globe, including many of the world’s leading private equity sponsors and financial institutions. He joins the Firm from Gibson, Dunn & Crutcher LLP. “Given his experience advising many of the most sophisticated private equity sponsors on a wide range of high-profile transactions, James is a perfect
Boosting Investment in R&I: €100,000 donation by kENUP Foundation to Malta’s COVID-19 R&D Fund1.8.2020 11:23:00 EEST | Press release
kENUP Foundation has presented €100,000 donation into Malta’s COVID-19 R&D Fund. The Fund is managed jointly by the Malta Council for Science and Technology (MCST) and Malta Enterprise with the support of the Ministry for Finance and Financial Services, and the Ministry for the Economy, Investment & Small Businesses. The Malta fund will see €5.3M funnelled into developing innovative and improved scientific and technological approaches to the challenges raised by COVID-19 and future pandemics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200801005005/en/ Boosting Investment in R&I: €100,000 donation by kENUP Foundation to Malta’s COVID-19 R&D Fund (Photo: Business Wire) kENUP, a Malta-based not-for-profit global partnership in innovation, promotes research-based innovation for Europe with public and societal benefit. Holm Keller, Chairman of kENUP Foundation said, “We are very grateful to the Maltese Government for the init
Dole Unveils Integrated Strategy Against Banana Disease31.7.2020 20:32:00 EEST | Press release
Dole Food Company today shared the company’s most recent update on its efforts to combat Fusarium Tropical Race 4 (TR4), a plant disease that poses an existential threat to bananas, a major staple crop for much of the world. Since the discovery of TR4 in northern Colombia one year ago, Dole swiftly ramped-up its TR4 response plan, implementing site-specific TR4 prevention activities throughout Latin America in coordination with local authorities and international experts to contain and prevent spread. A three-year containment program was immediately implemented in 2019 to ensure biosecurity protocols in every Dole banana farm, as well as those of Dole’s independent suppliers. Those protocols build upon best practices implemented in the banana producing countries where the disease has been successfully contained and are continually reviewed and strengthened per site—based upon the farm layout and location—to maximize the effectiveness of the risk-based mitigation plan. Dole also continu
Systemic Risk Council Issues Comments to Financial Stability Board31.7.2020 18:50:00 EEST | Press release
Today, the Systemic Risk Council (SRC) issued notification of its comments to the Financial Stability Board (FSB) concerning the FSB’s proposed guidance on the resolution of central-counterparty clearing houses (CCPs). The Systemic Risk Council (SRC) considers that the proposed guidance is not fit for purpose as it currently stands. The full text of the comments can be seen here. For further information contact David Evanson at email@example.com or 215.460.8139 or Bristol Voss at firstname.lastname@example.org or 917.817.0888. About The Systemic Risk Council The Systemic Risk Council (SRC or Council) is a private sector, non-partisan body of former government officials and financial and legal experts committed to addressing regulatory and structural issues relating to global systemic risk, with a particular focus on the United States and Europe. It has been formed to provide a strong, independent voice for reforms that are necessary to protect the public from financial instability. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom